Anheuser-Busch InBev (AV) is cited as an example of a parent company with a solvent subsidiary, similar to the proposed Grifols spinoff structure.
Source Post
🟢GRIFOLS: This SPANISH STOCK could have a 27% ANNUAL RETURN😲 + 👉USA SPINOFF Analysis
Systematic Value Investing ~ SVIApr 15, 2026
The creator analyzes Grifols (GRFS), a Spanish biopharma company specializing in plasma-derived medicines. Despite recent stock price declines and reputational issues stemming from a short-seller report, the company is seen as a turnaround candidate. Key catalysts include a potential US biofarma spinoff to reduce debt, improving credit ratings, and strong growth in its core immunoglobulin business. The analysis highlights Grifols' integrated value chain, competitive advantages, and potential for significant shareholder returns if operational improvements and debt reduction are successful.
Linked Mentions
Tickers discussed in this post
Novo Nordisk is mentioned as a comparison point for a typical biopharma company selling pills, contrasting with Grifols' industrial value chain.
Grifols (GRFS) is presented as a turnaround opportunity with a potential 27% annual return, driven by a potential US spinoff, debt reduction, and operational improvements.
Linked Signals
Tracked calls opened from this post
GRFS
buy opened Apr 15, 2026
-10.24%